Logo
Logo

About Sugammadex Sodium API

Product
  • Therapeutic CategoryCentral Nervous System (CNS)

  • CAS Number

    343306-79-6

  • API Technology

    Synthetic

  • Dose Form

    Injectable

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, Brazil DMF, EUDMF, Canada DMF, Japan DMF, Korea DMF, Russia DMF, China DMF

Mechanism of Action

BRIDION is a modified gamma cyclodextrin. It forms a complex with the neuromuscular blocking agents rocuronium and vecuronium, and it reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade induced by rocuronium and vecuronium.

Indication

BRIDION is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.

Related APIs

Apremilast (Amorphous & Form B)

Central Nervous System (CNS)

arrow

Atomoxetine Hydrochloride

Central Nervous System (CNS)

arrow

Benztropine Mesylate

Central Nervous System (CNS)

arrow

Dimethyl Fumarate

Central Nervous System (CNS)

arrow

Donepezil HCl

Central Nervous System (CNS)

arrow

Edaravone

Central Nervous System (CNS)

arrow

Eslicarbazepine Acetate

Central Nervous System (CNS)

arrow

Eszopiclone

Central Nervous System (CNS)

arrow

Levetiracetam

Central Nervous System (CNS)

arrow

Lumateperone Tosylate

Central Nervous System (CNS)

arrow

Lurasidone Hydrochloride

Central Nervous System (CNS)

arrow

Memantine Hydrochloride

Central Nervous System (CNS)

arrow

Pregabalin

Central Nervous System (CNS)

arrow

Quetiapine Fumarate

Central Nervous System (CNS)

arrow

Rimegepant

Central Nervous System (CNS)

arrow

Risperidone

Central Nervous System (CNS)

arrow

Rivastigmine Hydrogen Tartrate

Central Nervous System (CNS)

arrow

Ropinirole Hydrochloride

Central Nervous System (CNS)

arrow

Siponimod

Central Nervous System (CNS)

arrow

Sugammadex Sodium

Central Nervous System (CNS)

arrow

Tizanidine Hydrochloride

Central Nervous System (CNS)

arrow

Xanomeline

Central Nervous System (CNS)

arrow

Ziprasidone Hydrochloride

Central Nervous System (CNS)

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone

Related Resources

Managing the Product Life Cycle: Naproxen API and formulations

Managing the Product Life Cycle: Naproxen API and formulations

Naproxen is a non-steroidal anti-inflammatory drug (NSAID) used in treating pain, menstrual cramps, and inflammatory diseases such as rheumatoid arthritis and fever.SustainableSupply ChainGlobalRegulatory SupportMore than one decade ofNaproxen manufacturing> 1500metric tons per yearTrusted byleading pharmacompaniesNaproxen is a non-selective COX inhibitor and appears to exert anti-inflammatory action by reducing the production of inflammatory mediators like prostaglandins.Naproxen was patented in 1967 and approved for use in the United States in 1976.Naproxen by Dr. Reddy’sThe manufacturing of Naproxen and Naproxen Sodium has a long tradition at Dr. Reddy’s. We manufacture Naproxen for more than one decade at our cGMP site in Cuernavaca, Mexico. Today we are the 2nd largest manufacturer of Naproxen globally and reliably supply our global pharma customers with APIs and finished formulations.Active Pharmaceutical IngredientNaproxen Base and Naproxen NaManufactured at our dedicated cGMP facility in Cuernavaca, MexicoTotal capacity > 1500 MTCustomized particle sizeFinished Dosage FormNaproxen Na RxFormulated at our cGMP manufacturing site in Hyderabad, IndiaAddressing the changing market demands in the product life cyclesNaproxen has become one of the focus products of Dr. Reddy’s and our teams are working on constant improvements an capacity expansion to meet the changing market needs. Some of our approaches include.Robust supply chain – most of our key starting materials are now backward integrated and we have diversified our raw material sourcing through long term contracts and sourcing efficiencies to facilitate sustainable supplies.Capacity expansion – we have been working consistently over last one year to increase our manufacturing capacity by 50%.Continuous improvement – during the API life cycle, we regularly improve process efficiency and quality.Product life-cycle management – on request we are able to provide new formulations such as Naproxen Na OTCFacilitating formulation needs – on request we are able to supply formulators with DC grade granules of Natproxen Na to facilitate faster formulation development and manufacturing.
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.